Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,595 Million (Large Cap)
27.00
NA
1.13%
-0.48
14.93%
4.23
Revenue and Profits:
Net Sales:
261 Million
(Quarterly Results - Jun 2026)
Net Profit:
92 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-8.31%
0%
-8.31%
6 Months
-19.27%
0%
-19.27%
1 Year
-29.18%
0%
-29.18%
2 Years
20.75%
0%
20.75%
3 Years
-31.23%
0%
-31.23%
4 Years
-52.33%
0%
-52.33%
5 Years
-65.39%
0%
-65.39%
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
9.49%
EBIT Growth (5y)
6.57%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.53
Sales to Capital Employed (avg)
0.39
Tax Ratio
14.01%
Dividend Payout Ratio
34.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
33.71%
ROE (avg)
15.88%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
4.07
EV to EBIT
23.60
EV to EBITDA
21.35
EV to Capital Employed
6.91
EV to Sales
9.05
PEG Ratio
0.75
Dividend Yield
1.03%
ROCE (Latest)
29.30%
ROE (Latest)
14.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
261.30
255.80
2.15%
Operating Profit (PBDIT) excl Other Income
120.30
117.70
2.21%
Interest
0.20
0.20
Exceptional Items
1.60
0.90
77.78%
Consolidate Net Profit
92.10
98.90
-6.88%
Operating Profit Margin (Excl OI)
401.10%
407.40%
-0.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 2.15% vs 20.09% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -6.88% vs 43.96% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,058.80
922.30
14.80%
Operating Profit (PBDIT) excl Other Income
455.90
368.50
23.72%
Interest
1.10
1.30
-15.38%
Exceptional Items
3.10
1.00
210.00%
Consolidate Net Profit
368.10
304.30
20.97%
Operating Profit Margin (Excl OI)
376.30%
342.00%
3.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.80% vs 9.11% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 20.97% vs 2.98% in Dec 2024
About Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. 
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






